DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis
DURECT Corporation (DRRX)
Last durect corporation earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
durect.com/investors
Company Research
Source: PR Newswire
CUPERTINO, Calif., Jan. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study, applying DUR-928 topically to the plaque on one arm and the vehicle (placebo) to a similar plaque on the other arm daily for 28 days.DUR-928 did not demonstrate a benefit over vehicle (placebo) based on Investigator's Global Assessment (IGA), which was the scoring system for the primary analysis, or in any of the secondary analyses. Daily topical application of DUR-928 was well tolerated with no meaningful differences in adverse events between the treatment and vehicle (placebo) groups. There were no AEs attributed to the study drug. "Based on the top-line data, we do not plan to continue development of topical DUR-928 in psoriasis," said James E. Brown, President and CEO of DURECT. "With the recently announced positive results from our Phase
Show less
Read more
Impact Snapshot
Event Time:
DRRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRRX alerts
High impacting DURECT Corporation news events
Weekly update
A roundup of the hottest topics
DRRX
News
- DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- DURECT Co. (NASDAQ: DRRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
DRRX
Earnings
- 11/13/24 - Beat
DRRX
Analyst Actions
- 11/14/24 - HC Wainwright
DRRX
Sec Filings
- 11/29/24 - Form 8-K/A
- 11/25/24 - Form 8-K
- 11/19/24 - Form SC
- DRRX's page on the SEC website